The National Primary Health Care Development Agency (NPHCDA) has announced that Nigeria is to receive 3.92 million additional doses of Oxford-AstraZeneca vaccines from COVAX, by the end of July 2021.
The Executive Director, NPHCDA, Dr. Faisal Shuaib, made the announcement at a press briefing on Tuesday, in Abuja.
The News Agency Of Nigeria (NAN) recalled that Nigeria received its first consignment of 3.92 million doses of the Oxford-AstraZeneca COVID-19 vaccine through the COVID-19 Vaccines Global Assess Facility, COVAX, on March 2, 2021.
COVAX, an initiative co-led by the vaccine alliance, GAVI, and the World Health Organisation (WHO), aims to ensure equitable access to COVID-19 vaccines, by dividing about two billion doses across 92 low and middle-income countries.
The facility promises access to vaccines for up to 20 per cent of participating countries’ population with an initial supply beginning in the first quarter of the year, to immunise three per cent of their populations.
“We now have information that Nigeria will get 3.92m doses of Oxford-AstraZeneca by the end of July or early August, 2021.
“As we receive additional information on the exact dates in August, we will provide an update regarding timelines and details of this,” Shuaib said.
The NPHCDA boss stated that a recent research from Public Health England (PHE) shows that the Indian (Delta) variant B.1.617.2 was 92 per cent susceptible to Oxford/AstraZeneca.
“It is, therefore, comforting to know that the vaccine used in Nigeria can protect against this variant that caused high morbidity and mortality in India.
“However, it underscores the need for us to ramp up our vaccination to more Nigerians,” he stressed.